Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas

Abstract

A locoregional single dose of 188Re-labelled nimotuzumab of approximately 370 MBq could be used safely in the routine treatment of patients suffering with high-grade gliomas. The efficacy of this therapy needs to be evaluated in a phase II clinical trial.

Experimental approaches for the treatment of malignant gliomas

“…88 Re-nimotuzumab, a radiolabeled form of the antibody, was used to treat patients by local injection immediately following resection in a phase I trial. In this trial, doses were well tolerated, and signs of systemic antibody distribution were minimal, warranting phase II investigation (Torres et al, 2008). There is currently a phase III trial using nimotuzumab in conjunction with standard treatment for primary gliomas (NCT00753246).…”

Immunoscintigraphy With 99mTc-Nimotuzumab for Planning Immunotherapy in Patients With Bone Metastases Due to Prostate Cancer

“…Other studies have determined the in vivo specificity and the ratio of antibody uptake in tumor compared to normal tissues. 8,9 Nimotuzumab can be a safe, advantageous, and feasible therapeutic alternative as part of conventional treatment in health care conditions. 6,10…”

Delivery of Local Therapeutics to the brain: Working Toward Advancing Treatment for Malignant Gliomas

“…Direct injection into the ventricle and/or brain parenchyma requires repeated surgical procedures, which is associated with increased risk of intracranial hemorrhage, infection and malpositioned catheter, among others [58,62,68]. More importantly, this method is known to have poor drug distribution into the tumor tissue and the surrounding brain parenchyma [59,69]. Because it relies on a concentration gradient, the depth of distribution is often limited to approximately 3–5 mm, with an exponential decay in concentration from the injection site [59,69].…”

“…More importantly, this method is known to have poor drug distribution into the tumor tissue and the surrounding brain parenchyma [59,69]. Because it relies on a concentration gradient, the depth of distribution is often limited to approximately 3–5 mm, with an exponential decay in concentration from the injection site [59,69]. Thus, there is a high and often toxic concentration of drugs around the injection site and little drug presence in the surrounding areas [59].…”